# Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Canonical URL: https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corporate-developments
Ticker: BRNS
Company: Barinthus Biotherapeutics
Source: Barinthus Biotherapeutics
Published: 2026-04-30 11:30 EST
Original Source URL: https://investors.barinthusbio.com
## Summary

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending

## Article Body
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending
## Recent Company News
- 2026-04-30 11:30 EST — [Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2026-03-13 12:00 EST — [Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-12-10 13:00 EST — [Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease](https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease) — Source: Barinthus Biotherapeutics
- 2025-11-07 12:30 EST — [Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-third-quarter-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-09-30 12:01 EST — [Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases](https://biopharmsignal.com/news/BRNS/barinthus-biotherapeutics-to-combine-with-clywedog-therapeutics-to-target-metabolic-and-autoimmune-diseases) — Source: Barinthus Biotherapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)